IBA (Ion Beam Applications S.A., EURONEXT), a major global player in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), an emerging important radioisotope, which has significant potential in the treatment of cancer.
This
strategic R&D partnership consists of an in-depth evaluation of the
technical and economic feasibility of the project. Based on the outcome of this
first phase, SCK CEN and IBA plan to undertake the construction and
commissioning of a production unit on the SCK CEN site in Mol, Belgium.
To
read more please visit:
IBA
and SCK CEN join forces to enable production of Actinium-225
Source: IBA